JPH02218615A - Preventive for fish disease comprising water-soluble glucan - Google Patents
Preventive for fish disease comprising water-soluble glucanInfo
- Publication number
- JPH02218615A JPH02218615A JP1039954A JP3995489A JPH02218615A JP H02218615 A JPH02218615 A JP H02218615A JP 1039954 A JP1039954 A JP 1039954A JP 3995489 A JP3995489 A JP 3995489A JP H02218615 A JPH02218615 A JP H02218615A
- Authority
- JP
- Japan
- Prior art keywords
- fish
- glucan
- preventive
- water
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001503 Glucan Polymers 0.000 title claims abstract description 27
- 208000010824 fish disease Diseases 0.000 title claims abstract description 17
- 230000003449 preventive effect Effects 0.000 title abstract description 7
- 229920002305 Schizophyllan Polymers 0.000 claims abstract description 20
- 241000251468 Actinopterygii Species 0.000 claims abstract description 13
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims abstract description 10
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 5
- 230000002554 disease preventive effect Effects 0.000 claims description 4
- 241000252233 Cyprinus carpio Species 0.000 abstract description 10
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 241000276707 Tilapia Species 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 241000473391 Archosargus rhomboidalis Species 0.000 abstract description 2
- 206010003445 Ascites Diseases 0.000 abstract description 2
- 206010029443 Nocardia Infections Diseases 0.000 abstract description 2
- 206010029444 Nocardiosis Diseases 0.000 abstract description 2
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 abstract description 2
- 241000861914 Plecoglossus altivelis Species 0.000 abstract description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 abstract description 2
- 206010047400 Vibrio infections Diseases 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- 238000007654 immersion Methods 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000269979 Paralichthys olivaceus Species 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000607471 Edwardsiella tarda Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000221198 Basidiomycota Species 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 241000604754 Flexibacter Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Farming Of Fish And Shellfish (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、β−１，３−グルコシド結合からなる主鎖を
持つ水溶性グルカン（以下咳グルカンと略称する）を有
効成分とする魚病の予防剤（魚類の免疫調節剤）に関す
るものである。Detailed Description of the Invention [Field of Industrial Application] The present invention is directed to the treatment of fish diseases containing water-soluble glucan (hereinafter abbreviated as cough glucan) having a main chain consisting of β-1,3-glucoside bonds as an active ingredient. The present invention relates to a prophylactic agent (immunomodulator for fish).
従来、各種のキノコから抽出された多糖類が、人間を含
む哺乳動物の免疫能を増強することが知られている。こ
れらの多糖類は、主としてβ−１゜３−グルコシド結合
からなる主鎖にβ−１，６−グルコシド結合で分岐した
側鎖を持つグルカンである。It has been known that polysaccharides extracted from various mushrooms enhance the immune capacity of mammals including humans. These polysaccharides are glucans having a main chain mainly composed of β-1°3-glucosidic bonds and side chains branched by β-1,6-glucosidic bonds.
また、魚病に対してはワクチンによる防御方法や、抗生
物質による治療方法が知られている。さらに免疫増強活
性にもとづく魚病の予防・治療剤としてＰＫ−５６５（
特開昭６３−２３３９２３号）が知られているが、本発
明で利用するグルカンをこのような技術分野に利用する
ことは今までに知られていない。Furthermore, methods of protecting against fish diseases using vaccines and treatment methods using antibiotics are known. Furthermore, PK-565 (
JP-A No. 63-233923) is known, but the use of the glucan used in the present invention in such a technical field has not been known so far.
海洋資源の高度利用を目的として、近年多くの魚類の養
殖が広く行なわれるようになってきている。BACKGROUND ART In recent years, farming of many types of fish has become widespread for the purpose of advanced utilization of marine resources.
しかしながら魚類の養殖においては、しばしば細菌性又
はウィルス性のの魚病が発生し、それらによる損失は莫
大なものであるという報告がしばしばなされている。However, in fish farming, bacterial or viral fish diseases often occur, and it is often reported that the losses caused by these diseases are enormous.
このような魚病の予防（或は治＊＞を行うために、多く
の薬剤が開発されかつ一部は既に利用されている。その
薬剤の主体となるものは、抗生物質である。In order to prevent (or cure*) such fish diseases, many drugs have been developed and some are already in use.The main drugs are antibiotics.
しかしながら、抗生物質は、耐性菌の出現とか、抗生物
質の人体への移行というような問題があって、近年その
適用が規制される傾向にある。However, antibiotics have problems such as the appearance of resistant bacteria and the transfer of antibiotics to the human body, and in recent years their application has tended to be regulated.
一方、病原菌の死菌を利用したワクチンの利用も一部試
みられているが、適用可能な魚種が限られているため新
たな薬剤の出現が望まれていた。On the other hand, some attempts have been made to use vaccines using killed pathogenic bacteria, but since the applicable fish species are limited, there has been hope for the emergence of new drugs.
〔課題を解決するための手段〕
本発明者は、このような事情に鑑み、抗生物質以外の魚
病の予防剤、例えばワクチンの効果増強剤（アジユバン
ト）について研究を続け、本発明を完成した。[Means for Solving the Problems] In view of the above circumstances, the present inventor continued research on preventive agents for fish diseases other than antibiotics, such as vaccine effect enhancers (adjuvants), and completed the present invention. .
すなわち、本発明者は前記の目的のために、既に人間に
対して免疫調節効果を示す多くの生体反応修飾物質（Ｂ
ｉｏｌｏｇｉｃａｌ Ｒｅ５ｐｏｎｓｅ Ｍｏｄｉｆｉ
ｅｒ）について、それらが魚類に対し適用可能か否かを
鋭意研究した結果、β−１，３−グルコシド結合からな
る主鎖を持ち、且つ水溶性である多糖類が、特に強い魚
病の予防活性を有することを見出した。That is, for the above-mentioned purpose, the present inventors have developed a number of bioreaction modifiers (B
iological Re5ponse Modifi
As a result of intensive research into whether or not they are applicable to fish, we found that polysaccharides that have a main chain consisting of β-1,3-glucoside bonds and are water-soluble are particularly effective in preventing fish diseases. It was found that it has activity.
本発明の第１の目的は、該グルカンを有効成分として含
む魚病予防剤である。The first object of the present invention is a fish disease preventive agent containing the glucan as an active ingredient.
本発明の第２の目的は、該グルカンをアジュバント止し
て含有する免疫調節剤である。A second object of the present invention is an immunomodulator containing said glucan in adjuvant form.
以下、本発明を更に詳細に説明する。The present invention will be explained in more detail below.
本発明に於ては、β−１，３−グルコシド結合からなる
主鎖を持つ、水溶性グルカンを使用する。In the present invention, a water-soluble glucan having a main chain consisting of β-1,3-glucoside bonds is used.
該グルカンは、特定の担子菌（Ｓｃｈｉｚｏｐｈｙｌｌ
ｕｍｃｏｍｍｕｎｅ Ｆｒ１ｅｓ）、あるいは該担子菌
以外のある種の菌（Ｓｃｌｅｒｏｔｉｕｍ）を液内培養
することにより得られることが知られている。該グルカ
ンはβ−１゜３−グルコシド結合からなる主鎖にβ−１
，６−グルコシド結合で分岐した側鎖を持つのが一般的
であり、この側鎖の存在によって該グルカンは水溶性と
なっている。ところでβ−１，３−グルコシド結合の主
鎖を持つグルカンの中には、カードラン、ラミナリン等
で例示されるような側鎖を持たないものがいくつか知ら
れている。このようなβ−１，３−グルカンは、水に一
般に不溶性であり、それ放油性は一般に弱い。しかしな
がら、これら水不溶性β−１，３−グルカンを化学的に
修飾して水溶性としたとき、活性の発現されることが確
認された。The glucan is derived from a specific basidiomycete (Schizophyl
It is known that it can be obtained by submerged culture of Sclerotium umcommune Frles) or a certain type of fungus other than the Basidiomycetes (Sclerotium). The glucan has β-1 in its main chain consisting of β-1゜3-glucoside bonds.
, 6-glucosidic bonds, and the presence of this side chain makes the glucan water-soluble. By the way, some glucans having a main chain of β-1,3-glucoside bonds are known to have no side chains, such as curdlan and laminarin. Such β-1,3-glucans are generally insoluble in water and generally have weak oil release properties. However, when these water-insoluble β-1,3-glucans were chemically modified to become water-soluble, it was confirmed that the activity was expressed.
該グルカンとしては、次の一般式で示すようなシゾフィ
ラン（特許公告４６−３７８７３号）及びスクレログル
カン（Ｕ Ｓ Ｐ １．０６１．０４３）を例示するこ
とが出来る。Examples of the glucan include schizophyllan (Patent Publication No. 46-37873) and scleroglucan (USP 1.061.043) as shown by the following general formula.
なお、グルカンに関連する特許としては、米国特許４，
０９８．６６１ （１９７８年７月４日）、英国特許（
１９６３年１０月２３日）及びカナダ特許（１９７５年
５月２７日）等を挙げることができ、これらの公知刊行
物に記載の方法及び化合物は、必要により本発明の一部
を構成するものとする。In addition, patents related to glucan include U.S. Patent 4,
098.661 (July 4, 1978), British Patent (
(October 23, 1963) and Canadian Patent (May 27, 1975), etc., and the methods and compounds described in these known publications are considered to form part of the present invention, if necessary. do.
本発明に於て、グルカンは、水溶液濃度０６０１〜１％
に於て使用する。In the present invention, glucan has an aqueous solution concentration of 0601 to 1%.
Used in.
該水溶液は魚の種類によって、海水に相応する程度まで
の塩を含有していてもよい。Depending on the type of fish, the aqueous solution may contain salts to a degree commensurate with seawater.
投与方法としては、経口投与法又は腹腔（筋肉内注射）
法、又は浸漬法等による。経口投与は魚鱗と一緒であっ
てもよい。The administration method is oral administration or intraperitoneal (intramuscular injection).
method, immersion method, etc. Oral administration may be with fish scales.
さらにその投与量は３■〜２０■／ｋｇ（体重）の割合
とすることが望ましい。Furthermore, it is desirable that the dosage be at a rate of 3 to 20 cm/kg (body weight).
本発明が適用される魚病としては、例えばハマチ、タイ
、ヒラメ、フグ、アユ、コイ、ティラピア、ニジマス、
ウナギ等のビブリオ症（ビブリオ・アンギュイラルム）
、類結節症（パスツーレラ・ビスシシーダ）、連鎖球菌
症（ストレプトコッカス・エスピー）、ノカルジア症（
ノカルジア・カンバチ−）、滑走細菌症（フレキシバク
ター・マリナス）、エドワジコラ症（エドワジェラ・タ
ルダ）、エロモナス症（エロモナス・ハイドロフィラ）
等の各種細菌感染症、腹水症、リンホシスチス症、口白
症等のウィルス感染症等が挙げられる。Examples of fish diseases to which the present invention is applied include yellowtail, sea bream, flounder, pufferfish, sweetfish, carp, tilapia, rainbow trout,
Vibriosis in eels, etc. (Vibrio angularum)
, nodulariasis (Pasteurella viscicida), streptococcus (Streptococcus sp.), nocardiosis (
Nocardia campatii), sliding bacteriosis (Flexibacter marinus), edwardicholosis (edwardigera tarda), aeromoniasis (eromonas hydrophila)
Examples include various bacterial infections such as ascites, lymphocystosis, and viral infections such as white palatia.
実施例１
コイとティラビアのエドワジェラ症に対する効果■方
法
水温２５℃で飼育した平均体重３０ｇのコイと平均体重
５５ｇのティラビＴに、実験開始初日と４日目に、シゾ
フィランまたはスクレログルカンを体重１ ｋｇ当り５
■の割合で復腔内投与（Ｓ度０．１％生理食塩水溶液）
した。なお対照魚には生理食塩水のみを投与した。つい
で、７日目に魚体通過エドワジェラ・タルダ
（Ｂｄｗａｒｄｓｉｃｌｌａ ｔａｒｄａ）を１．５
ｘ ｌ Ｏ’ ｃｆｕ ／尾接種して感染させた。夫々
につき１．２．３．４及び５日後の生存率を調べた。Example 1 Effects of carp and tilavia on edwarmerosis
Carp with an average weight of 30 g and Tirabi T with an average weight of 55 g raised at a water temperature of 25°C were treated with 5 doses of schizophyllan or scleroglucan per 1 kg of body weight on the first and fourth day of the experiment.
Intravenous administration at the rate of (S degree 0.1% physiological saline solution)
did. Note that only physiological saline was administered to control fish. Next, on the 7th day, 1.5 Bdwardsiclla tarda were passed through the fish body.
Infection was done by inoculating x l O' cfu/tail. The survival rates after 1, 2, 3, 4, and 5 days were examined, respectively.
■結 果
コイにエドワジェラ・タルダを感染させた場合のレゾフ
ィラン投与群、スクレログルカン投与群及び対照群の生
存率（％）を第１表に示した。■Results Table 1 shows the survival rates (%) of the resofilan-administered group, the scleroglucan-administered group, and the control group when carp were infected with Edwardsella tarda.
菓１表
ティラピアにエドワジエラ・タルダを感染させた場合の
レゾフィラン投与群、スクレログルカン投与群及び対照
群の生存率（％）を第２表に示した。Table 1 shows the survival rates (%) of the resofilan-administered group, the scleroglucan-administered group, and the control group when tilapia were infected with Edwardsiella tarda.
第２表
実施例２
コイ血中の補体第３成分（Ｃ３）含量の変化■方 法
実施例１と同様にして、コイにシゾフィランとスクレロ
グルカンを投与した。７日目に尾静脈から採血し、血中
の０３含量を測定した。Table 2 Example 2 Changes in complement component 3 (C3) content in carp blood ■Method Schizophyllan and scleroglucan were administered to carp in the same manner as in Example 1. On the 7th day, blood was collected from the tail vein, and the content of 03 in the blood was measured.
■結 果
シゾフィラン及びスクレログルカン投与後のコイ血中の
補体第３成分（Ｃ３）含量（ｕ／顎）０を第３表にまと
めて示す。■Results Table 3 summarizes the complement component 3 (C3) content (u/jaw) 0 in carp blood after administration of schizophyllan and scleroglucan.
第 ３ 表
＊ ３ＸＩＯ’個の感作ヒツジ赤血球の５０％を溶血
させるＣ３量を１単位（１，ｕ ）と規定した。Table 3 * The amount of C3 that caused hemolysis of 50% of 3XIO' sensitized sheep red blood cells was defined as 1 unit (1,u).
実施例３
ワクチン投与後のコイの血中凝集抗体価の変化■方 法
水温２５℃で飼育したコイに、エドワジエラ・タルダ死
菌ワクチン１０＋ｏｇ湿重量／尾と、シゾフィラン又は
スクレログルカン５０μｇ／尾とを混合接種し、５、ｌ
０１１５日後の血中凝集抗体価を測定した。Example 3 Changes in blood agglutination antibody titer of carp after vaccination ■ Method Carp reared at a water temperature of 25°C were treated with 10+og wet weight/tail of killed Edwardsiella tarda vaccine and 50μg/tail of Schizophyllan or scleroglucan. Mixed inoculation of 5, l
After 0.115 days, the blood agglutination antibody titer was measured.
■結 果 血中凝集抗体価の経日変化を第４表にまとめて示す。■Results Table 4 summarizes the daily changes in the blood agglutinating antibody titer.
第 ４ 表
イ及びティラビアにシゾフィラン又はスクレログルカン
を投与すると、魚病、例えばエドワジエラ・タルダ感染
時の生存率が高まる。すなわち魚病の予防剤として有効
である。これらの多糖類、グルカンは感染初期に効果を
発揮し、又、血中のＣ３含量を増大させることから、非
特異的免疫機構（補体、食細胞等）の活性化に関与して
いると考えられる。Table 4 Administration of Schizophyllan or Scleroglucan to Tirabia and Tirabia increases the survival rate when infected with fish diseases such as Edwardsiella tarda. In other words, it is effective as a preventive agent for fish diseases. These polysaccharides and glucans are effective at the early stage of infection and increase the C3 content in the blood, so they are thought to be involved in the activation of non-specific immune mechanisms (complement, phagocytes, etc.). Conceivable.
さらに実施例３において、エドワジェラ・タルダワクチ
ンと、シゾフィラン（又はスクレログルカン）とを混合
接種した際、凝集抗体価がワクチンの単独投与の場合よ
り高くなっていることから、これらの多糖類、グルカン
がアジュバント活性を有することが明らかである。Furthermore, in Example 3, when the Edwardsella tarda vaccine and Schizophyllan (or scleroglucan) were administered together, the agglutinated antibody titer was higher than when the vaccine was administered alone. It is clear that the compound has adjuvant activity.
さらに、ワクチンで処理された魚に、後日（すなわち免
疫後）、該グルカンを投与してもアジュバント活性のあ
ることがｗ認された。Furthermore, it was found that the glucan had adjuvant activity even when administered to fish treated with the vaccine at a later date (ie, after immunization).
実施例１及び２の結果から明らかなように、コ手続補正
書
４．１４
平成元年 月 日
（リ 明細書を下表の通り訂正する。As is clear from the results of Examples 1 and 2, the description is corrected as shown in the table below.
２、発明の名称
水溶性グルカンからなる魚病の予防剤
４、代理人
（２）明細書第１０頁第３表中、対照群の項の単位５、
補正命令の日付
自
発
（３）同書第１１頁第４表中、レゾフィラン投与群の日
数５の欄“１：１４”を「１：４」と訂正する。2. Name of the invention Preventive agent for fish diseases consisting of water-soluble glucan 4. Agent (2) Unit 5 in the control group section in Table 3, page 10 of the specification.
Date of amendment order Voluntary (3) In Table 4, page 11 of the same document, the column "1:14" in the number of days 5 for the resofilan administration group is corrected to "1:4".
６、補正の対象 明細書の発明の詳細な説明の欄6. Subject of correction Detailed description of the invention in the specification
Claims (7)
、水溶性グルカンを含有する魚病予防剤。(1) A fish disease preventive agent containing water-soluble glucan having a main chain consisting of β-1,3-glucoside bonds.
の魚病予防剤。(2) The fish disease preventive agent according to claim (1), wherein the glucan is schizophyllan.
記載の魚病予防剤。(3) Claim (1) wherein the glucan is scleroglucan
Fish disease preventive agent as described.
、水溶性グルカンを有効成分として含む魚類の免疫調節
剤。(4) A fish immunomodulator containing water-soluble glucan as an active ingredient, which has a main chain consisting of β-1,3-glucoside bonds.
の魚類の免疫調節剤。(5) The immunomodulator for fish according to claim (4), wherein the glucan is schizophyllan.
記載の魚類の免疫調節剤。(6) Claim (4) wherein the glucan is scleroglucan.
Fish immunomodulators as described.
疫調節剤。(7) The fish immunomodulator according to claim (4), which contains a vaccine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1039954A JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1039954A JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02218615A true JPH02218615A (en) | 1990-08-31 |
| JPH062676B2 JPH062676B2 (en) | 1994-01-12 |
Family
ID=12567350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1039954A Expired - Fee Related JPH062676B2 (en) | 1989-02-20 | 1989-02-20 | Preventive agent for fish diseases consisting of water-soluble glucan |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH062676B2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04247032A (en) * | 1991-02-01 | 1992-09-03 | Taito Kk | Preventive for infectious disease of crustacea or host defense enhanser |
| US5320849A (en) * | 1990-06-25 | 1994-06-14 | Taito Co., Ltd. | Anti-virus agent |
| US5786343A (en) * | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| JP2002542181A (en) * | 1999-04-20 | 2002-12-10 | バイオテク エイエスエイ | Decorative cosmetic preparations |
| WO2004039378A1 (en) * | 2002-11-01 | 2004-05-13 | Zoolife International Limited | Preparations comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| JP2006166806A (en) * | 2004-12-16 | 2006-06-29 | Oriental Yeast Co Ltd | Functional fish culture feed |
| JP2011504487A (en) * | 2007-11-26 | 2011-02-10 | ノバルティス アーゲー | Glucan with adjuvant |
| US7914799B2 (en) * | 2001-08-27 | 2011-03-29 | Immunitor USA, Inc. | Anti-fungal composition |
| JP4820005B2 (en) * | 1999-03-12 | 2011-11-24 | バイオテク エイエスエイ | Cosmetics and / or pharmaceuticals |
| US9439955B2 (en) | 2007-11-26 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Conjugated β-1,3-linked glucans |
| CN110692558A (en) * | 2019-11-13 | 2020-01-17 | 扬州科润德机械有限公司 | Fish swarm epidemic prevention method |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5153188B2 (en) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1 / Th2 balance improver |
-
1989
- 1989-02-20 JP JP1039954A patent/JPH062676B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| BULLETIN OF THE JAPANESE SOCIETY OF SCIENTIFIC FISHERIES=1983 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5320849A (en) * | 1990-06-25 | 1994-06-14 | Taito Co., Ltd. | Anti-virus agent |
| JPH04247032A (en) * | 1991-02-01 | 1992-09-03 | Taito Kk | Preventive for infectious disease of crustacea or host defense enhanser |
| US5786343A (en) * | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| JP4820005B2 (en) * | 1999-03-12 | 2011-11-24 | バイオテク エイエスエイ | Cosmetics and / or pharmaceuticals |
| JP2002542181A (en) * | 1999-04-20 | 2002-12-10 | バイオテク エイエスエイ | Decorative cosmetic preparations |
| JP4664509B2 (en) * | 1999-04-20 | 2011-04-06 | バイオテク エイエスエイ | Decorative cosmetic preparations |
| US7914799B2 (en) * | 2001-08-27 | 2011-03-29 | Immunitor USA, Inc. | Anti-fungal composition |
| WO2004039378A1 (en) * | 2002-11-01 | 2004-05-13 | Zoolife International Limited | Preparations comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| JP2006166806A (en) * | 2004-12-16 | 2006-06-29 | Oriental Yeast Co Ltd | Functional fish culture feed |
| JP2011504487A (en) * | 2007-11-26 | 2011-02-10 | ノバルティス アーゲー | Glucan with adjuvant |
| US9439955B2 (en) | 2007-11-26 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Conjugated β-1,3-linked glucans |
| US9439954B2 (en) | 2007-11-26 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Conjugated beta-1,3-linked glucans |
| CN110692558A (en) * | 2019-11-13 | 2020-01-17 | 扬州科润德机械有限公司 | Fish swarm epidemic prevention method |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH062676B2 (en) | 1994-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ogier de Baulny et al. | Effect of long-term oral administration of beta-glucan as an immunostimulant or an adjuvant on some non-specific parameters of the immune response of turbot Scophthalmus maximus | |
| JP2828799B2 (en) | Method for producing yeast glucan | |
| Park et al. | Enhanced resistance against Edwardsiella tarda infection in tilapia (Oreochromis niloticus) by administration of protein-bound polysaccharide | |
| Mastan | Use of immunostimulants in aquaculture disease management | |
| JPH02218615A (en) | Preventive for fish disease comprising water-soluble glucan | |
| Kamilya et al. | In vitro effects of bovine lactoferrin, mushroom glucan and Abrus agglutinin on Indian major carp, catla (Catla catla) head kidney leukocytes | |
| JPH05503952A (en) | Method for producing soluble glucans | |
| JPH05502018A (en) | Immune system activation method | |
| Samuel et al. | Effect of Laminaran [β (1, 3)-D-Glucan] on the protective immunity of blue gourami, Trichogaster trichopterusagainstAeromonas hydrophila | |
| Perine et al. | Immunity to syphilis I. Passive transfer in rabbits with hyperimmune serum | |
| EP0384323B2 (en) | Composition and process to enhance the efficacy of a fish vaccine | |
| Farooqi et al. | Immunostimulants for aquaculture health management | |
| Cook et al. | Protective effect of glucan against visceral leishmaniasis in hamsters | |
| US5641761A (en) | Preventive agent against infectious disease of crustacea | |
| US5189028A (en) | Composition and method to enhance the efficacy of a fish vaccine and to stimulate the immune system of fish | |
| JP3522772B2 (en) | Vaccine immunopotentiator | |
| Kogut et al. | Evaluation of Salmonella enteritidis‐immune lymphokines on host resistance to Salmonella enterica ser. gallinarum infection in broiler chicks | |
| JP5240811B2 (en) | Japanese red sea bream sliding bacteriosis vaccine, Japanese red sea bream sliding bacteriosis vaccine composition and method for preventing red sea bream sliding bacteriosis | |
| Sen et al. | Immune responses and protection in rohu vaccinated against Aeromonas hydrophila infection | |
| KR20010098698A (en) | Combined inactivated vaccine for iridovirus infectious diseases, streptococcus infectious diseases and combined diseases thereof in fishes | |
| US4083959A (en) | Therapeutical method for treating infection of mink hemorrhagic pneumonitis | |
| Dalmo | Immunostimulatory β (1, 3)-D-glucans; prophylactic drugs against threatening infectious diseases of fish | |
| Verwey et al. | Effect of caronamide upon penicillin therapy of experimental pneumococcus and typhoid infections in mice | |
| JP5863839B2 (en) | Vaccine against Vibrio infection in shrimp and method for producing the same | |
| RU2712237C1 (en) | Method for improving the immunobiological reactivity of calves in specific prevention of viral respiratory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |